The stock of Blueprint Medicines Corp (BPMC) has gone down by -1.39% for the week, with a 27.54% rise in the past month and a 37.76% rise in the past quarter. The volatility ratio for the week is 3.18%, and the volatility levels for the past 30 days are 4.11% for BPMC. The simple moving average for the past 20 days is 10.71% for BPMC’s stock, with a 16.45% simple moving average for the past 200 days.
Is It Worth Investing in Blueprint Medicines Corp (NASDAQ: BPMC) Right Now?
Additionally, the 36-month beta value for BPMC is 0.62. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 5 rating it as “overweight,” 5 rating it as “hold,” and 1 rating it as “sell.”
The public float for BPMC is 62.28M and currently, short sellers hold a 8.26% ratio of that float. The average trading volume of BPMC on January 30, 2025 was 735.62K shares.
BPMC) stock’s latest price update
Blueprint Medicines Corp (NASDAQ: BPMC)’s stock price has dropped by -0.26 in relation to previous closing price of 114.32. Nevertheless, the company has seen a loss of -1.39% in its stock price over the last five trading days. zacks.com reported 2025-01-14 that BPMC stock rallies 18% on the company’s optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.
Analysts’ Opinion of BPMC
Many brokerage firms have already submitted their reports for BPMC stocks, with JP Morgan repeating the rating for BPMC by listing it as a “Overweight.” The predicted price for BPMC in the upcoming period, according to JP Morgan is $126 based on the research report published on November 14, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see BPMC reach a price target of $88. The rating they have provided for BPMC stocks is “Neutral” according to the report published on October 24th, 2024.
Stephens gave a rating of “Overweight” to BPMC, setting the target price at $140 in the report published on May 14th of the previous year.
BPMC Trading at 17.25% from the 50-Day Moving Average
After a stumble in the market that brought BPMC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.46% of loss for the given period.
Volatility was left at 4.11%, however, over the last 30 days, the volatility rate increased by 3.18%, as shares surge +31.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.17% upper at present.
During the last 5 trading sessions, BPMC fell by -1.42%, which changed the moving average for the period of 200-days by +30.65% in comparison to the 20-day moving average, which settled at $102.99. In addition, Blueprint Medicines Corp saw 30.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BPMC starting from Haviland Kate, who sale 1,446 shares at the price of $110.24 back on Jan 21 ’25. After this action, Haviland Kate now owns 149,378 shares of Blueprint Medicines Corp, valued at $159,407 using the latest closing price.
Rossi Christina, the CHIEF OPERATING OFFICER of Blueprint Medicines Corp, sale 2,274 shares at $110.14 during a trade that took place back on Jan 21 ’25, which means that Rossi Christina is holding 67,109 shares at $250,455 based on the most recent closing price.
Stock Fundamentals for BPMC
Current profitability levels for the company are sitting at:
- -0.64 for the present operating margin
- 0.95 for the gross margin
The net margin for Blueprint Medicines Corp stands at -0.29. The total capital return value is set at -0.29. Equity return is now at value -49.66, with -11.11 for asset returns.
Based on Blueprint Medicines Corp (BPMC), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at -0.51. The debt to equity ratio resting at 1.51. The interest coverage ratio of the stock is -4.2.
Currently, EBITDA for the company is -470.36 million with net debt to EBITDA at -1.59. When we switch over and look at the enterprise to sales, we see a ratio of 17.49. The receivables turnover for the company is 6.6for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.32.
Conclusion
In conclusion, Blueprint Medicines Corp (BPMC) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
